• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Immunol Invest . Prevalence of SARS-CoV-2 Specific Antibodies in Asymptomatic Hemodialysis Patients

tetano

Editor, Senior Moderator
Immunol Invest


. 2021 Mar 23;1-12.
doi: 10.1080/08820139.2021.1899202. Online ahead of print.
Prevalence of SARS-CoV-2 Specific Antibodies in Asymptomatic Hemodialysis Patients


Jalal Etemadi[SUP] 1 2 [/SUP], Shima Bordbar[SUP] 1 [/SUP], Mohammad Sadegh Soltani-Zangbar[SUP] 3 4 [/SUP], Mahsa Hajivalili[SUP] 5 [/SUP], Leili Aghebati-Maleki[SUP] 6 [/SUP], Roza Motavalli[SUP] 1 2 3 [/SUP], Ata Mahmoodpoor[SUP] 7 [/SUP], Sima Shahmohammadi-Farid[SUP] 4 [/SUP], Sima Abedi Azar[SUP] 1 [/SUP], Bahram Niknafs[SUP] 1 [/SUP], Leila Roshangar[SUP] 2 [/SUP], Zohreh Babaloo[SUP] 4 [/SUP], Javad Ahmadian Heris[SUP] 8 [/SUP], Maryam Hosseini[SUP] 9 [/SUP], Oldouz Shareghi-Oskoue[SUP] 2 [/SUP], Forough Parhizkar[SUP] 2 [/SUP], Hamid Tayebi Khosroshahi[SUP] 1 [/SUP], Mehdi Yousefi[SUP] 2 4 [/SUP]



Affiliations

Abstract

Background: Since the outbreak of the new coronavirus pandemic, the importance of carrying out an infection check to prevent acquisition and transmission among end-stage renal disease patients (ESRD) under maintenance hemodialysis (MHD) has become a major concern in the health care system. Applying serology screening tests could enlighten the view with regards to disease prevalence in dialysis wards.Methods: We subjected 328 end-stage renal disease patients to maintenance hemodialysis. After dividing patients into suspicious and non-suspicious groups for COVID-19 infection based on their clinical manifestation, they were investigated for SARS-CoV-2 specific IgM and IgG screening against nucleoprotein (NP), spike protein (SP), and receptor-binding domain (RBD), utilizing our recently developed ELISA tests.Results: We found that approximately 10.1% of asymptomatically tested cases were antibody positive. Although IgG positivity showed a higher prevalence than IgM across all three virus antigen subunits, there were no significant differences among mentioned immunoglobulins of the studied groups. The most prevalent antibody was from the IgG subtype against virus nucleoprotein (NP), while the lowest prevalence was attributed to receptor-binding domain (RBD) IgM.Conclusion: High seropositive rate among asymptomatic end-stage renal disease patients, as a sample of high-risk population, reflected the importance of considering SARS-CoV-2 specific antibody screening for disease containment.

Keywords: COVID-19; SARS-CoV-2; asymptomatic; maintenance hemodialysis; serology.
 
Back
Top Bottom